ArticleJournal of medicinal chemistry2021
A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects.
Open access · bronzeAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 69 citations in OpenAlex.
- Assessment of Abuse Potential-Related Effects of Oral Dried Kratom Leaf Powder in Healthy Normal Participants Following Single and Multiple Daily Doses.Drug testing and analysis · 2026Trial
- Atypical respiration patterns of kratom alkaloids.The Journal of pharmacology and experimental therapeutics · 2026Article
- Investigating Opioid Receptor Activity through Biocatalytic Halogenation and Oxidation of Mitragynine.ACS chemical biology · 2026Article
- 7-OH and kratom vaping products: an emerging public health threat.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Identification of small molecule ligands for GPR83 that modulate morphine antinociception and reward.Molecular pharmacology · 2026Article
- Differential Effects of Sodium on Agonist-Induced Conformational Transitions and Signaling at μ and κ Opioid Receptors.Biochemistry · 2025Article
- Semi-synthesis in the exploration of opioid-targeting natural products.Natural product reports · 2025Review
- Differential effects of sodium on agonist-induced conformational transitions and signaling at μ and κ opioid receptors.bioRxiv : the preprint server for biology · 2025Article
- Comprehensive pharmacokinetics and ADME evaluation of Akuamma alkaloids.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2025Article
- Evaluating the drug interactions in kratom usage: clinical application.Expert opinion on drug metabolism & toxicology · 2025Review
- Synthesis and Pharmacology of a Morphinan-Derived Dual Mu-Kappa Opioid Receptor Agonist Analgesic.ACS chemical neuroscience · 2025Article
- Total synthesis and biological activity of "carbamorphine": O-to-CHProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Discovery of Iboga-Derived Ligands for the Sigma‑2 Receptor.ACS bio & med chem Au · 2025Article
- Exploring marine-derived bacterial compounds targeting the μ-opioid receptor agonists through metabolic profiling to molecular modeling.Scientific reports · 2025Article
- Article
- Synthesis and Biological Evaluation of Metamorphine: A Morphine-Metamizole Adduct from Patient-Controlled Analgesia Pumps.ACS pharmacology & translational science · 2025Article
- Structure-guided design of partial agonists at an opioid receptor.Nature communications · 2025Article
- Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.Nature communications · 2024Article
- Signaling Modulation Mediated by Ligand Water Interactions with the Sodium Site at μOR.ACS central science · 2024Article
- Structure-Guided Design of Partial Agonists at an Opioid Receptor.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 9 institutions in 1 country.
Soumen ChakrabortyCenter for Clinical Pharmacology, University of Health Sciences & Pharmacy at St. Louis and Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Jeffrey F DiBertoDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina 27599, United States.
Abdelfattah FaouziCenter for Clinical Pharmacology, University of Health Sciences & Pharmacy at St. Louis and Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Sarah M BernhardCenter for Clinical Pharmacology, University of Health Sciences & Pharmacy at St. Louis and Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Anna M GutridgeDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.
Steven RamseyDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0001-7441-3228
Yuchen ZhouDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Davide ProvasiDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Nitin NuthikattuCenter for Clinical Pharmacology, University of Health Sciences & Pharmacy at St. Louis and Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Rahul JilakaraCenter for Clinical Pharmacology, University of Health Sciences & Pharmacy at St. Louis and Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Melissa N F NelsonDepartments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, and Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, United States.
Wesley B AsherDepartments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, and Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, United States.
Shainnel O EansDepartment of Pharmacodynamics, University of Florida, Gainesville, Florida 032610, United States.
Lisa L WilsonDepartment of Pharmacodynamics, University of Florida, Gainesville, Florida 032610, United States.ORCID 0000-0001-7770-8726
Satyanarayana M ChintalaDepartment of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Marta FilizolaDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0002-4382-8276
Richard M van RijnDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0002-9957-1633
Elyssa B MargolisDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California 94158, United States.
Bryan L RothDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-0561-6520
Jay P McLaughlinDepartment of Pharmacodynamics, University of Florida, Gainesville, Florida 032610, United States.ORCID 0000-0001-9851-9342
Tao CheCenter for Clinical Pharmacology, University of Health Sciences & Pharmacy at St. Louis and Washington University School of Medicine, St. Louis, Missouri 63110, United States.ORCID 0000-0002-1620-3027
Dalibor SamesDepartment of Chemistry, Columbia University, New York 10027, United States.
Jonathan A JavitchDepartments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, and Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, United States.ORCID 0000-0001-7395-2967
Susruta MajumdarCenter for Clinical Pharmacology, University of Health Sciences & Pharmacy at St. Louis and Washington University School of Medicine, St. Louis, Missouri 63110, United States.ORCID 0000-0002-2931-3823
University of Health Sciences and Pharmacy · USIcahn School of Medicine at Mount Sinai · USNew York Psychoanalytic Society and Institute · USUniversity of Florida · USUniversity of North Carolina at Chapel Hill · USPurdue University West Lafayette · USColumbia University · USUniversity of California, San Francisco · USWashington University in St. Louis · US
Funding
Arylepoxamides: A new class of potent, safer analgesicsUH3DA048379 · NIDA · SPARIAN BIOSCIENCES, INC. · PI REICH, JEFFREY · 2021 to 2023
$13.7MArylepoxamides: A new class of potent, safer analgesicsUG3DA048379 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI PAN, YING-XIAN · 2019 to 2021
$6.8MChemistry and Biology of Mitragynine AlkaloidsR01DA046487 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI MAJUMDAR, SUSRUTA, SAMES, DALIBOR · 2018 to 2022
$3.0MMolecular and Dynamic Insights into the Function of GPCRs Involved in Drug AbuseR01DA045473 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FILIZOLA, MARTA · 2018 to 2022
$2.2MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MTransforming Genomics with 5 PB Big Omics Data Engine Cray CS300-AC SupercomputerS10OD018522 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2014 to 2014
$1.9MDynamic Mechanisms of GPCRs Targeted by Drugs of AbuseR01DA034049 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FILIZOLA, MARTA · 2012 to 2016
$1.8MPharmacological Probes based on mitragynine pseudoindoxylR33DA045884 · NIDA · ST. LOUIS COLLEGE OF PHARMACY · PI MAJUMDAR, SUSRUTA, SAMES, DALIBOR · 2020 to 2021
$792kAnalgesics targeting truncated 6transmembrane exon 11 variants of MOR-1 (6TM-E11)R21DA034106 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI MAJUMDAR, SUSRUTA · 2012 to 2013
$443kPharmacological Probes based on mitragynine pseudoindoxylR21DA045884 · NIDA · ST. LOUIS COLLEGE OF PHARMACY · PI MAJUMDAR, SUSRUTA, SAMES, DALIBOR · 2018 to 2019
$437kOpioidergic alkaloids from Mitragynia Speciosa (kratom) as novel treatment for alcohol use disorderR21AA026949 · NIAAA · PURDUE UNIVERSITY · PI VAN RIJN, RICHARD M. · 2018 to 2019
$421kNIAAA NIH HHS R21 AA026949NIDA NIH HHS R01 DA034049NIDA NIH HHS R01 DA045473NIDA NIH HHS R01 DA046487NIDA NIH HHS R21 DA034106NIDA NIH HHS R21 DA045884NIDA NIH HHS R33 DA045884NIDA NIH HHS UG3 DA048379NIDA NIH HHS UH3 DA048379NIH HHS S10 OD018522NIH HHS S10 OD026880
Abstract
Mitragynine and 7-hydroxymitragynine (7OH) are the major alkaloids mediating the biological actions of the psychoactive plant kratom. To investigate the structure-activity relationships of mitragynine/7OH templates, we diversified the aromatic ring of the indole at the C9, C10, and C12 positions and investigated their G-protein and arrestin signaling mediated by mu opioid receptors (MOR). Three synthesized lead C9 analogs replacing the 9-OCH
Indexed as
Analgesics, OpioidAnimalsMaleMiceMice, Inbred C57BLMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureRatsRats, Sprague-DawleyReceptors, Opioid, muSecologanin Tryptamine AlkaloidsStructure-Activity RelationshipAnalgesics, OpioidmitragynineReceptors, Opioid, muSecologanin Tryptamine Alkaloids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.